fep blue cross blue shield glp 1 coverage Drops of GLP-1 Obesity Drugs Provider Update December 2025 |

10.2165/00003495-200868150-00005 103 KumarS.MittalA.MittalA

I hope that the changing landscape will decrease cost, increase production and improve access to these medications. Patents for semaglutide are now expiring in several countries, paving the way for cheaper generics

Half of Americans want to lose weight, Gallup (2025) Local Blue Cross and Blue Shield companies and licensees, BCBS FDA approves weight-loss drug Contrave, Harvard Health (2014) Formularies, HealthAffairs.org (2017) Save on Contrave, Currax Pharmaceuticals, LLC Contrave, DailyMed (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

These medications (liraglutide 3mg/Saxenda and semaglutide 2.4mg/Wegovy) may be prescribed for adults with a BMI of 35 kg/m or greater (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) who have at least one weight-related comorbidity and have not achieved adequate weight loss through dietary and exercise interventions